Europe – UK launch for Alliance’s pregnancy anti-nausea and vomiting drug

Alliance Pharma has announced the launch of Xonvea in the UK to treat nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management.

Xonvea is a fixed-dose combination of 10mg doxylamine succinate (histamine H1 receptor antagonist) and 10mg pyridoxine hydrochloride (vitamin B6 pro-drug) formulated as lactose-free, gastro-resistant, delayed-release tablets specifically for the treatment of the condition.

NVP is one of the most common reasons for pregnant women to be admitted to hospital. In 2016/17, there were 33,071 hospital admissions for NVP in England, resulting in 36,171 bed days, while a recent study estimated that the condition could cost the NHS in the UK up to £62.3 million per year…